{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:12:22Z","timestamp":1794107542125,"version":"4.8.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ygyno.2025.09.017","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T03:57:28Z","timestamp":1760500648000},"page":"131-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Immunohistochemistry, next generation sequencing (NGS), and whole exome sequencing concordance in HER2 testing in uterine serous carcinoma: a retrospective analysis"],"prefix":"10.1016","volume":"202","author":[{"given":"Victoria M.","family":"Ettorre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bellone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Buza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias Max Philipp","family":"Hartwich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Demirkiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Greenman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro D.","family":"Santin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2025.09.017_bb0005","series-title":"SEER Cancer Stat Facts: Uterine Cancer","author":"Institute NC","year":"2025"},{"key":"10.1016\/j.ygyno.2025.09.017_bb0010","first-page":"258","article-title":"Current recommendations and recent progress in endometrial cancer","volume":"69","author":"Brooks","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2025.09.017_bb0015","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2025.09.017_bb0020","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.2012.48.2596","article-title":"Type I and II endometrial cancers: have they different risk factors?","volume":"31","author":"Setiawan","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.09.017_bb0025","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2025.09.017_bb0030","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research N","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2025.09.017_bb0035","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ygyno.2021.04.029","article-title":"Uterine serous carcinoma","volume":"162","author":"Bogani","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.09.017_bb0040","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2025.09.017_bb0045","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1073\/pnas.1222577110","article-title":"Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma","volume":"110","author":"Zhao","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ygyno.2025.09.017_bb0050","first-page":"0","article-title":"Characteristics of HER2 gene amplification by fluorescence in situ hybridization in endometrial serous carcinoma","volume":"146","author":"Buza","year":"2022","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.ygyno.2025.09.017_bb0055","series-title":"FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors","author":"FDA","year":"2024"},{"key":"10.1016\/j.ygyno.2025.09.017_bb0060","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.09.017_bb0065","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/852748","article-title":"Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol. Biol. Int."},{"key":"10.1016\/j.ygyno.2025.09.017_bb0070","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrgastro.2011.81","article-title":"Anti-HER agents in gastric cancer: from bench to bedside","volume":"8","author":"Fornaro","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ygyno.2025.09.017_bb0075","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1586\/era.10.226","article-title":"HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies","volume":"11","author":"Gajria","year":"2011","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.ygyno.2025.09.017_bb0080","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2025.09.017_bb0085","article-title":"The rapidly evolving landscape of human epidermal growth factor receptor 2 (HER2) testing in endometrial carcinoma and other gynecologic malignancies","author":"Buza","year":"2025","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.ygyno.2025.09.017_bb0090","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5858\/arpa.2020-0207-RA","article-title":"HER2 testing in endometrial serous carcinoma: time for standardized pathology practice to meet the clinical demand","volume":"145","author":"Buza","year":"2021","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.ygyno.2025.09.017_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159176","article-title":"HER2\/CEP17 ratios and clinical outcome in HER2-positive early breast cancer undergoing trastuzumab-containing therapy","volume":"11","author":"Stocker","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2025.09.017_bb0100","article-title":"Reporting results of biomarker testing of specimens from patients with carcinoma of gynecologic origin: the updated College of American Pathologists Protocol","author":"Turashvili","year":"2025","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.ygyno.2025.09.017_bb0105","series-title":"Calling Somatic SNVs and Indels with Mutect2","author":"Benjamin","year":"2019"},{"key":"10.1016\/j.ygyno.2025.09.017_bb0110","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkw520","article-title":"FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing","volume":"44","author":"Shen","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ygyno.2025.09.017_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004873","article-title":"CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing","volume":"12","author":"Talevich","year":"2016","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.ygyno.2025.09.017_bb0120","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/PGP.0000000000000690","article-title":"Does specimen type have an impact on HER2 status in endometrial serous carcinoma? Discordant HER2 status of paired endometrial biopsy and hysterectomy specimens in the presence of frequent Intratumoral heterogeneity","volume":"40","author":"Rottmann","year":"2021","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2025.09.017_bb0125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/PGP.0000000000000711","article-title":"HER2 testing and reporting in endometrial serous carcinoma: practical recommendations for HER2 immunohistochemistry and fluorescent in situ hybridization: proceedings of the ISGyP companion society session at the 2020 USCAP annual meeting","volume":"40","author":"Buza","year":"2021","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2025.09.017_bb0130","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","article-title":"Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): updated overall survival analysis","volume":"26","author":"Fader","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2025.09.017_bb0135","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.09.017_bb0140","series-title":"NCCN Clinical Practice Guidelines in Oncology: uterine Neoplasms","author":"Network","year":"2025"},{"key":"10.1016\/j.ygyno.2025.09.017_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2021.39.15_suppl.1036","article-title":"Concordance of HER2+ status by IHC\/ISH and ERBB2 status by NGS in a real-world clinicogenomic database and analysis of outcomes in patients (pts) with metastatic breast cancer (mBC)","volume":"39","author":"Cho-Phan","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.09.017_bb0150","series-title":"FoundationOne CDX Technical Information FDA Label","author":"FoundationOne","year":"2024"},{"key":"10.1016\/j.ygyno.2025.09.017_bb0155","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jmoldx.2016.09.010","article-title":"Next-generation assessment of human epidermal growth factor receptor 2 (ERBB2) amplification status: clinical validation in the context of a hybrid capture-based, comprehensive solid tumor genomic profiling assay","volume":"19","author":"Ross","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.ygyno.2025.09.017_bb0160","first-page":"43","article-title":"Concordance between human epidermal growth factor receptor 2 (HER2) status by immunohistochemistry (IHC) and next-generation sequencing (NGS) in tissue and blood samples from gastric and gastroesophageal junction cancers (GC\/GEJC)","author":"Maron","year":"2025","journal-title":"ASCO"},{"key":"10.1016\/j.ygyno.2025.09.017_bb0165","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1186\/s12885-024-12482-5","article-title":"Clinical application of targeted tumour sequencing tests for detecting ERBB2 amplification and optimizing anti-HER2 therapy in gastric cancer","volume":"24","author":"Ichikawa","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2025.09.017_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2023.06.569","article-title":"Next-generation sequencing complements conventional clinical HER2 testing for advanced or recurrent endometrial tumors","volume":"176","author":"Lee","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.09.017_bb0175","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41379-020-00695-5","article-title":"Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays","volume":"34","author":"Robinson","year":"2021","journal-title":"Mod. Pathol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825010145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825010145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:38:38Z","timestamp":1780407518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825010145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":35,"alternative-id":["S0090825825010145"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.09.017","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunohistochemistry, next generation sequencing (NGS), and whole exome sequencing concordance in HER2 testing in uterine serous carcinoma: a retrospective analysis","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}